湖南埃威格林医药科技

Hunan Evergreen Pharmaceutical Technology is a clinical-stage biotechnology company headquartered in Changsha, China, specializing in the discovery and development of innovative small molecule therapeutics. Founded in 2017, the company focuses on high-impact therapeutic areas including oncology and metabolic diseases. Its research strategy emphasizes the development of next-generation inhibitors and agonists, such as its fourth-generation EGFR inhibitor for lung cancer and a small molecule GLP-1 receptor agonist for metabolic disorders. Evergreen Pharma leverages an integrated R&D platform to advance candidates from early discovery through clinical proof-of-concept. The company aims to address significant unmet medical needs by providing more effective and accessible treatment options for global patient populations.